The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion ... Concerns Over CVS Setback Are Overblown, Analysts Say The collaboration focuses on discovering and developing RNA ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc ... into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.